| |
 |
| |
AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2009
(Rs. In Lacs except per share data) |
| Particulars |
Quarter ended |
Quarter ended |
Half Year Ended |
Half Year Ended |
Year ended |
| 30th Sep 2009 |
30th Sep 2008 |
30th Sep 2009 |
30th Sep 2008 |
31st Mar 2009 |
1.
|
(a) |
(Net) Sales / Income from operations |
11,968 |
9,414 |
23,167 |
18,800 |
37,650 |
| |
(b) |
Other Operating Income |
- |
- |
- |
- |
- |
| 2. |
Expenditure |
|
|
|
|
|
| |
(a) |
(Increase) / Decrease in stock in trade & WIP. |
(323) |
(1,348) |
(104) |
(1,187) |
695 |
| |
(b) |
Consumption of raw materials. |
6,321 |
6,953 |
11,855 |
12,131 |
21,077 |
| |
(c) |
Purchase of Traded Goods |
2,025 |
670 |
3,755 |
1,520 |
3,443 |
| |
(d) |
Employees cost |
346 |
267 |
667 |
523 |
1,114 |
| |
(e) |
Depreciation |
334 |
262 |
662 |
519 |
1,104 |
| |
(f) |
Other expenditure |
1,726 |
1,475 |
3,160 |
2,778 |
5,648 |
| |
(g) |
Total Expenditure |
10,429 |
8,279 |
19,995 |
16,284 |
33,081 |
| 3. |
Profit from Operations before Other Income, Interest & Exceptional Item |
1,539 |
1,136 |
3,172 |
2,517 |
4,570 |
| 4. |
Other Income |
29 |
2 |
31 |
6 |
17 |
| 5. |
Profit before Interest & Exceptional Items |
1,568 |
1,138 |
3,203 |
2,523 |
4,587 |
| 6. |
Interest |
409 |
604 |
832 |
1,164 |
2,272 |
| 7. |
Profit after Interest but before Exceptional Items |
1,159 |
534 |
2,371 |
1,359 |
2,315 |
| 8. |
Exceptional Items |
- |
- |
- |
- |
- |
| 9. |
Profit from Ordinary Activities before Tax |
1,159 |
534 |
2,371 |
1,359 |
2,315 |
| 10. |
Tax Expenses (Includes) |
481 |
193 |
962 |
365 |
810 |
| |
(a) |
Provision for Taxation |
414 |
126 |
826 |
233 |
540 |
| |
(b) |
Provision for FBT |
- |
4 |
1 |
7 |
15 |
| |
(c) |
Provision for Deffered Taxation |
67 |
63 |
135 |
125 |
255 |
| 11. |
Net profit from ordinary Activities after Tax |
678 |
341 |
1,409 |
994 |
1,505 |
| 12. |
Extraordinay Item (net of tax expenses ) |
- |
- |
- |
- |
- |
| 13. |
Net Profit for the period |
678 |
341 |
1,409 |
994 |
1,505 |
| 14. |
Paid-up Equity Share Capital of Rs.10/- each. |
1,171 |
1,171 |
1,711 |
1,171 |
1,171 |
| 15. |
Reserves & Surplus (excluding revaluation reserves) |
- |
- |
- |
- |
- |
| 16. |
Basic E P S(in Rs.) |
5.79 |
2.92 |
12.04 |
8.49 |
12.85 |
| 17. |
Public shareholding |
|
|
|
|
|
| |
-Number of Shares |
5864219 |
5766044 |
5864219 |
5766044 |
5495949 |
| |
-Percentage of Total Shareholding |
50.08 |
49.25 |
50.08 |
49.25 |
46.94 |
| 18. |
Promoters & Promoter Group |
|
|
|
|
|
| |
Shareholding |
|
|
|
|
|
| |
(a) |
Pledged/Encumbered |
|
|
|
|
|
| |
-Number of Shares |
NIL |
N.A |
NIL |
N.A |
NIL |
| |
-Percentage of shares( as a percentage of the total shareholding of promoter and promoter group) |
NIL |
N.A |
NIL |
N.A |
NIL |
| |
-Percentage of shares( as a percentage of total sharecapital of the Company) |
NIL |
N.A |
NIL |
N.A |
NIL |
| |
(b) |
Non-encumbered |
|
|
|
|
|
| |
-Number of Shares |
5844331 |
N.A |
5844331 |
N.A |
6212601 |
| |
-Percentage of shares( as a percentage of the total shareholding of promoter and promoter group) |
100 |
N.A |
100 |
N.A |
100 |
| |
-Percentage of shares( as a percentage of total sharecapital of the Company) |
49.92* |
N.A |
49.92* |
N.A |
53.06 |
| |
|
|
|
|
|
|
| |
* Reclassified |
|
|
|
|
|
|
| |
| Notes : |
| 1. |
The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 30th October, 2009 |
| 2. |
Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement as per AS - 17 'Segment Reporting' is not attracted. |
| 3. |
The figures of the previous periods have been regrouped and rearranged wherever necessary. |
| 4. |
Number of Investors complaints (i) pending at the beginning of quarter 1 (ii) received during the quarter : 10 (Iii) redressed : 10 (iv) pending at the end of the quarter : 1. |
| For and on behalf of the Board |
| FOR AARTI DRUGS LIMITED |
| |
Sd/- |
| Place : Mumbai |
Harshit M Savla |
| Date : 30th Oct, 2009 |
(Jt. Managing Director) |
|
| |
| |
|
|
| |
| |
 |
| |
|
|